Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 99 of 317 for:    BENDAMUSTINE

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01754870
Recruitment Status : Withdrawn (slow accrual)
First Posted : December 21, 2012
Last Update Posted : November 15, 2019
Sponsor:
Collaborators:
Celgene Corporation
Genentech, Inc.
Information provided by (Responsible Party):
University of Wisconsin, Madison

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014